Abstract
Breast cancer has no simple explanation. I tested the hypothesis that Epstein-Barr (EBV) infections promote the disease because they disable breast cancer safeguards. I used bioinformatics of public information from approximately 2100 breast cancers. Results demonstrate that chromosome breakpoints in breast and ovarian cancer cluster around the same breakpoints in diverse EBV-associated cancers. Cancers unrelated to EBV do not have these clusters. Breast cancers overexpress a methylation signature caused by active EBV infection. EBV remnants interspace between MHC genes and piRNA clusters as CRISPR- like evidence of past infection. I then found breast cancer breakpoints cluster around EBV docking sites. This clustering occurs because EBV breaks chromosomes and then damages breast cancers safeguards: BRCA1/2 pathways, SMC5/6, and mitotic controls. Finally, EBV causes the same losses that drive breast cancer metastasis. Activated EBV bypasses all these safeguards without large numbers of particles or continuing presence. Immunizing against EBV proteins may prevent breast, ovarian, and other cancers.
Summary Human papilloma virus promotes cervical cancer because it disables tumor suppressors. EBV in breast cancer resembles this model. EBV variants disable a variety of molecular and cellular safeguards that protect against breast cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data are all openly available from peer-reviewed publications and may be accessed from original publications. These publications are all listed in the references. A summary of much of the data used is included as a supplementary file.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.